A Phase II Study of CD30-Directed CAR T-Cell Therapy in People with Hodgkin Lymphoma

Share
Print

Full Title

A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically-Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT - TESSCAR001)

Purpose

With CAR T-cell therapy, white blood cells called T cells are removed from the patient, altered in the laboratory to recognize a protein on the patient’s cancer cells, multiplied to larger numbers, and returned to the patient to find and destroy cancer cells. In this study, researchers are assessing the safety and effectiveness of a new CAR T-cell therapy that is designed to recognize a protein called CD30 on Hodgkin lymphoma cells. They are evaluating this treatment in children, young adults, and adults with classical Hodgkin lymphoma that has come back or continued to grow even though they have already received anticancer therapy.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have classical Hodgkin lymphoma that makes the CD30 protein.
  • Patients’ cancers must persist despite multiple prior regimens of therapy.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people ages 12 to 75.

For more information about this study and to ask about eligibility, please contact the office of Dr. Connie Batlevi at 646-608-3707.

Protocol

20-424

Phase

II

Disease Status

Relapsed or Refractory

Investigator